Burning Rock Biotech Ltd (BNR)

Burning Rock Biotech Ltd is a healthcare company whose American depositary shares trade on the NASDAQ under the symbol BNR. The company develops and commercializes cancer therapy selection tests in China and the United States, with activities organized across Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. Its portfolio includes next-generation sequencing-based tissue and liquid biopsy tests used in cancer therapy selection and prognosis prediction across multiple cancer types, including lung, gastrointestinal, prostate, breast, lymphoma, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. Key offerings include OncoScreen Focus, OncoScreen Plus, OncoCompass Plus, OncoCompass Target, ColonCore, CanCatch, OncoMaster, and Magnis BR-customized products. Burning Rock also supports laboratory equipment and reagent kit sales and has collaborations and development agreements with companies such as Myriad Genetics, AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.